Metastatic Castration-resistant Prostate Cancer Clinical Trials

44 studies are recruiting for metastatic castration-resistant prostate cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer

   Background: Head and neck cancers (HNCs) account for about 5% of all cancers worldwide. They grow in the mouth, throat, nasal cavity, or salivary glands. Prostate cancer is the most common cancer in men in the United States. Survival rates for these cancers are lower than 50% if they spread to othe…

   Stage

   Phase 1

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT07667400 on ClinicalTrials.gov

2. A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

   This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Ironwood Cancer & Research Centers, Chandler, Arizona

   Locations

   231 in total

   Run by

   Pfizer

   See if you can join NCT06629779 on ClinicalTrials.gov

3. The COSMYC Trial (COmbined Suppression of MYC)

   This research is being done to determine if receiving the combination of testosterone and ZEN-3694 followed by the combination of enzalutamide plus ZEN-3694 will decrease the size of tumors in patients with prostate cancer that has become resistant to castration and other therapies. The investigato…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland

   Run by

   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

   See if you can join NCT06922318 on ClinicalTrials.gov

4. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

   This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 to 100

   Site

   University of Alabama at Birmingham Hospital, Birmingham, Alabama

   Locations

   38 in total

   Run by

   Janux Therapeutics

   See if you can join NCT05519449 on ClinicalTrials.gov

5. Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

   Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozole. Identify dose range for optimization/recommended dose for further clinical evaluation. Phase II: Further characterize the safety and tolerability of GVV858 in combination with…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Emory University, Atlanta, Georgia

   Locations

   16 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT07288359 on ClinicalTrials.gov

6. A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

   This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Diego Moores Cancer Center, La Jolla, California

   Locations

   29 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT07244341 on ClinicalTrials.gov

7. Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

   This study compares two different imaging procedures to each other, one using positron emission tomography (PET) with fluorothymidine F-18 (FLT) (FLT PET for short), and the other using chemical shift-encoded (CSE) magnetic resonance imaging (MRI) or CSE-MRI for short, to determine specifically if …

   Stage

   EARLY_Phase 1

   Ages

   18 and older

   Site

   University of Wisconsin Carbone Cancer Center, Madison, Wisconsin

   Run by

   University of Wisconsin, Madison

   See if you can join NCT07609225 on ClinicalTrials.gov

8. A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

   Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is safe, increasing doses alone and in combination with darolutamide, whether it is effective …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of California San Francisco, San Francisco, California

   Locations

   13 in total

   Run by

   K36 Therapeutics, Inc.

   See if you can join NCT07103018 on ClinicalTrials.gov

9. A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

   The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).

   Stage

   Phase 3

   Ages

   18 and older

   Site

   City of Hope Cancer Center Phoenix, Goodyear, Arizona

   Locations

   159 in total

   Run by

   Amgen

   See if you can join NCT07213674 on ClinicalTrials.gov

10. AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

    The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Dothan, Alabama

    Locations

    151 in total

    Run by

    AstraZeneca

    See if you can join NCT07611110 on ClinicalTrials.gov

11. A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

    The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Miami, Florida

    Locations

    16 in total

    Run by

    AstraZeneca

    See if you can join NCT06879041 on ClinicalTrials.gov

12. A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer

    This study will test whether BNT324 is safe and works better against metastatic castration-resistant prostate cancer (mCRPC) than the current standard of care (SoC) chemotherapy, which is docetaxel (given together with the steroid medicines prednisone or prednisolone). The study will include partic…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Sansum Clinic, Santa Barbara, California

    Locations

    52 in total

    Run by

    BioNTech SE

    See if you can join NCT07365995 on ClinicalTrials.gov

13. JUR-003 in Adult Patients With Metastatic Prostate Cancer

    JUR-003-ONC-101 is a first-in-human Phase 1a/1b open-label, multicenter study to evaluate the safety, tolerability, PK, pharmacodynamics, and preliminary anti-tumor activity of JUR-003 in patients with prostate cancer. This study is divided into 2 parts: Phase-1a Dose Escalation (Part 1), and Phase…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Midwest, Grand Rapids, Michigan

    Locations

    4 in total

    Run by

    Juri Biosciences, Inc.

    See if you can join NCT07824349 on ClinicalTrials.gov

14. A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer

    This study will evaluate the efficacy and safety of the combination of inavolisib plus enzalutamide compared with physician's choice of alternative androgen receptor pathway inhibitor (ARPi) or docetaxel in biomarker-selected participants with metastatic castrate-resistant prostate cancer (mCRPC) w…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    VA West Los Angeles Medical Center - (CRS) - NAVREF - PPDS, Los Angeles, California

    Locations

    48 in total

    Run by

    Hoffmann-La Roche

    See if you can join NCT07287150 on ClinicalTrials.gov

15. FOG-001 in Locally Advanced or Metastatic Solid Tumors

    The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors or in participants with familial adenomatous polyposis (FAP).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    33 in total

    Run by

    Parabilis Medicines, Inc.

    See if you can join NCT05919264 on ClinicalTrials.gov

16. A Study to Learn About the Investigational Drug Rinzimetostat (ORIC-944) in Patients With mCRPC Who Were Previously Treated With Abiraterone Acetate (Himalayas-1)

    Himalayas-1 is a randomized, open-label, global, multicenter phase 3 study evaluating whether the combination of rinzimetostat with darolutamide is more effective compared to physician's choice of control; ARPI (darolutamide or enzalutamide) or docetaxel for treating patients with metastatic castra…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    SSAK Partners, LLC, Coral Springs, Florida

    Locations

    12 in total

    Run by

    ORIC Pharmaceuticals

    See if you can join NCT07723248 on ClinicalTrials.gov

17. Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

    The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA) positive.

    Stage

    Phase 2

    Ages

    19 and older

    Site

    Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center, Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT06738303 on ClinicalTrials.gov

18. A Study in Patients With Metastatic Castration-Resistant Prostate Cancer

    The goal of this clinical trial is to find out if FX-111 is safe enough to permit further studies in adult male participants with metastatic castration-resistant prostate cancer (mCRPC). It will also study the drug's pharmacokinetics (how the body breaks down FX-111) and how well FX-111 treats mCRP…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Los Angeles, Los Angeles, California

    Locations

    10 in total

    Run by

    Flare Therapeutics Inc.

    See if you can join NCT07719361 on ClinicalTrials.gov

19. Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

    TROPION-PanTumor03 will investigate the safety, tolerability, and anti-tumour activity of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced/Metastatic Solid Tumours.

    Stage

    Phase 2

    Ages

    18 to 130

    Site

    Research Site, Los Angeles, California

    Locations

    96 in total

    Run by

    AstraZeneca

    See if you can join NCT05489211 on ClinicalTrials.gov

20. Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

    This is a single-center, open-label, study of Prostate-Specific Membrane Antigen (PSMA)-targeted radionuclide therapy with 177Lu-PSMA-617 in combination with pembrolizumab in participants with metastatic castrate-resistant prostate cancer (mCRPC) who have previously progressed on at least one prior…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University of California, San Francisco, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT05766371 on ClinicalTrials.gov

21. Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

    This is an open-label, single-arm phase II study of bipolar androgen therapy (BAT) given in addition with standard of care Sipuleucel-T to determine the interferon (IFN) gamma Enzyme-linked Immunospot (ELISPOT) response rate to PA2024 (an engineered fusion protein of prostatic acid phosphatase and …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Yale Cancer Center, New Haven, Connecticut

    Run by

    Yale University

    See if you can join NCT06100705 on ClinicalTrials.gov

22. A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

    Hormone therapy, or androgen deprivation therapy (ADT) is a standard way to treat prostate cancer. It works by reducing the amount of the main male sex hormone, testosterone in the body. Androgen receptor pathway inhibitors (ARPIs) are another type of hormone therapy. They either slow down how much…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Clearview Cancer Institute, Huntsville, Alabama

    Locations

    54 in total

    Run by

    Astellas Pharma Global Development, Inc.

    See if you can join NCT07005154 on ClinicalTrials.gov

23. Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    6 in total

    Run by

    Janux Therapeutics

    See if you can join NCT07545811 on ClinicalTrials.gov

24. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

    The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Winship Cancer Institute of Emory University, Atlanta, Georgia

    Locations

    80 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT04104776 on ClinicalTrials.gov

25. A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    The purpose of this study is to evaluate the safety, efficacy, tolerability, and pharmacokinetics (PK) of FG-3246, a cluster of differentiation 46 (CD46) targeting antibody-drug conjugate (ADC), in the treatment of participants with mCRPC who have progressed following treatment with one prior secon…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Western Regional Medical Center - City of Hope Phoenix Goodyear, Goodyear, Arizona

    Locations

    23 in total

    Run by

    Kyntra Bio

    See if you can join NCT06842498 on ClinicalTrials.gov